2018 revenue: $13.6 billion
The world’s largest orthopedic medical device company is enjoying momentum at the start of the year. Stryker’s bottom line more than tripled to $3.6 billion in 2018, and sales were up 9.3% to $13.6 billion.
Stryker (NYSE:SYK) officials see the company bolstering its position in the spine market as it integrates K2M, which the company acquired for about $1.4 billion in November 2018. Kalamazoo, Mich.–based Stryker also expects double-digit percentage growth in the number of Mako systems for robot-assisted knee and hip surgery implanted this year, said Katherine Owen, Stryker’s VP of strategy and investor relations, speaking during a January earnings call transcribed by Seeking Alpha.
SVB Leerink analysts wrote during the AAOS annual meeting in March that Mako remains best-in-class in an expanding category: “We continue to hear from docs that if one wants a true robotics platform, Mako is the way to go.”
Stryker also used AAOS to introduce a redesigned ReUnion S humeral stem for shoulder arthroplasty, and Stryker’s trauma and extremities division launched Adapt for Gamma3 augmented reality software.
You may also like: